ALFA Finder| Revenue growth | FY26 Consolidated Revenue down 7.85% YoY. |
|---|---|
| Margins | Consolidated EBITDA margin at 19.97%; PBT hit by higher finance/depreciation costs. |
| Order book | Pending 15cr litre ethanol allocation represents ~₹1,062 Cr revenue potential. |
| Demand visibility | Visibility improved by E20-E30 mandates and SAF policy shifts. |
| Management confidence | Confident in long-term biofuel story despite short-term OMC offtake disruptions. |
Growth
Consolidated Revenue fell 7.85% YoY; PAT dropped 33.94% YoY. CBG segment revenue grew 50.80% YoY.
Outlook
Investing ₹2,250 Cr in SAF facility; 4 CBG plants under construction with Sumitomo JV; targeting 100 retail outlets.
Risks
Significant impact from sharp reduction in ethanol offtake by OMCs and judicial delays in allocation implementation.
Earnings Call filed with BSE, NSE: TRUALT. Summary written with AI assistance from the document.
TruAlt Bioenergy Ltd: key numbers
- Share price
- ₹350.00
- Market cap
- ₹3,001 Cr
- Revenue (annual)
- ₹1,728 Cr
- Net profit (annual)
- ₹95.95 Cr
- P/E (TTM)
- 13.6×Sector 29.0×
- Promoter holding
- 71.38%+0.83% QoQ
- FII holding
- 0.62%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from TruAlt Bioenergy Ltd
All →TruAlt Bioenergy Other Announcement
TruAlt Bioenergy filed Crisil's monitoring agency report for the quarter ended 30 September 2026 on its Rs 750 crore IPO proceeds. The report notes no deviation from the IPO objects.
TruAlt Bioenergy Earnings Call Transcript: Key Takeaways
TruAlt reported massive 606% YoY revenue growth, turning profitable despite raw material price surges. Management is pivoting from ethanol to high-margin CBG to insulate from feedstock volatility.
TruAlt Bioenergy Investor Presentation: Key Takeaways
Q2 FY27 consolidated total income ₹823.74 Cr, PAT ₹34.99 Cr, EBITDA margin 12.47%. H1 PAT ₹94.27 Cr, EBITDA ₹233.92 Cr (16.27% margin). Strategy: integrated bioenergy across ethanol, CBG, SAF, retail.
TruAlt Bioenergy Results Update
TruAlt Bioenergy reported H1 FY27 revenue of ₹1,437.98 crore, EBITDA of ₹233.92 crore and PAT of ₹94.27 crore via press release. Results reverse last year's H1 loss.
TruAlt Bioenergy Q2 FY27 Results: Turns Profitable, Net Profit ₹35 Cr
TruAlt Bioenergy Ltd reported revenue from operations of ₹811.1 Cr (+605.9% YoY) and net profit of ₹35 Cr for Q2 FY27.
- Key figure
- Net profit ₹35 Cr
TruAlt Bioenergy Management Change
Mr. Monu Kumar resigned as Company Secretary and Compliance Officer of TruAlt Bioenergy Limited, effective October 16, 2026, due to personal reasons.